creating the building blocks of tomorrow's smart medicine
Biodegradable, biocompatible polymers
2024 CSPS & CC-CRS Symposium
Meros Polymers is a proud sponsor and exibitor at the 2024 Canadian Society for Pharmaceutical Sciences Annual Symposium, hosted at the University of Alberta from June 10-13. Visit the Meros table to explore formulation and controlled release possiblities for your therapeutic.
About Meros Polymers
Our Mission
Our Services
Our Mission
Inspired to solve the problems associated with many existing medicines, we have adapted materials with a long history of safe human use to create nanoscale drug delivery polymers highly effective in dissolving, delivering and slowing the release of drugs.
We are committed to helping our partners utilize our micelle-based technology to improve the performance of their therapeutic products.
Our Team
Our Services
Our Mission
Dr. Afsaneh Lavasanifar, Ph.D., Pharm.D.
Vice-President & CSO
Afsaneh Lavasanifar is a Professor at the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, and the lead inventor of the Meros drug delivery technologies. She is an established expert in drug delivery, focusing on polymer-based micelles for injectable formulations.
Our Services
Our Services
Our Services
Meros advanced formulation technology
can generate unique, targeted therapies,
creating competitive advantage via product
line extensions, repurposing / repositioning older drugs and improving new compounds that show marginal performance on their own.
We offer custom formulation of small molecules and bioligics to optimize therapeutic performance.
Our Technology
Our micelles are less than 100 nanometers in size.
Meros technology provides enhanced solubility, stability and sustained release of active pharmaceutical ingredients in parenteral formulations for multiple routes of drug
administration.
Meros Products
Functionalized Caprolactone Monomer
Functionalized Caprolactone Monomer
Functionalized Caprolactone Monomer
Our unique functionalized caprolactone monomer provides versatility in engineering custom delivery agents, whether on its own or as part of a polymer. The innovative addition of pendant groups on caprolactone transforms it into a highly customizable loading vehicle which can encapsulate a broad range of therapeutics by physical or chemical means.
Our technology enhances the inherent biocompatibility and systemic stability of caprolactone, adding endless engineering possibilities.
ExCell(TM) Diblock Copolymers
Functionalized Caprolactone Monomer
Functionalized Caprolactone Monomer
ExCell micelles are small (<100 nm) particles with a hydrophilic exterior and a hydrophobic core (drug reservoir) that are formed from block co-polymers of polyethylene glycol and the Meros monomer. ExCell copolymers can be custom formulated with therapeutic actives to self-assemble into drug-loaded micelles, creating ExCell™ injectable formulations. ExCell can be formulated using conventional methods and facilities. and can be further processed by lyophilisation or spray-drying.
PolyGel (TM)
Custom Formulation
Custom Formulation
Meros tri-block copolymers form transparent
thermo-responsive gels. PolyGel™ is a liquid at room temperature and forms a viscous gel close to body temperature. It is suitable for topical use and subcutaneous injection.
Custom Formulation
Custom Formulation
Custom Formulation
Research Grade Polymers for Purchase and/or Custom Formulation
Meros can provide research grade polymers for in-house testing.
We have an extensive catalog of ExCell variations available for purchase and we can create custom polymers to enhance delivery of small and large molecules.
IN MEMORIAM
It is with deepest sorrow that we announce the passing of Meros President and long time contributor, Mr Don Hughes on January 16, 2024. Don was a major supporter of Meros who played a significant role in the promotion of the company from a business point of view. He was a true supporter and advocate for scientific advancements in health and medical field with a sweet spot for home grown and Alberta based technologies. He will be greatly missed by the Alberta technology advancement community in general and by Meros Polymers Inc. in particular.
Publications
ExCell (TM)
Sadat S, Vakili MR, Paiva IM, Weinfeld M, Lavasanifar A, Development of self-associating SN-38-conjugated poly(ethylene oxide)-poly(ester) micelles for colorectal cancer, Pharmaceutics, In Press.
Paiva I, Mattingly S, Wuest M, Leier S, Vakili MR, Weinfeld M, Lavasanifar A, Wuest F (2020) Synthesis and Analysis of 64Cu-Labeled GE11-Modified Polymeric Micellar
Al-Lawati, Hanan; Vakili, Mohammad; Lavasanifar, Afsaneh; Ahmed, Surur; Jamali, Fakhreddin (2020) “Reduced heart exposure of diclofenac by its polymeric micellar formulation, normalizes CYP- mediated metabolism of arachidonic acid imbalance in adjuvant arthritis rat model: Implications in reduced cardiovascular side effects of diclofenac by nano-drug delivery” Molecular Pharmaceutics, 17 (4), 1377-1386Nanoparticles for EGFR-Targeted Molecular Imaging in a Colorectal Cancer Model, Molecular Pharmaceutics, 17(5) 1470-1481.
Saqr A, Vakili MR*, Huang YH, Lai R, Lavasanifar A* (2019) Development of Traceable Retuximab-Modified PEO Polyester Micelles by post insertion of PEG-phospholipids for targeting of B-cell Lymphoma, ACS Omega, 4(20):18867-18879.
Al-Lawati H, Vakili MR, Lavasanifar A, Ahmed S, Jamali F. (2019) Delivery and biodistribution of traceable polymeric micellar diclofenac in the rat., Journal of Pharmaceutical Sciences, 108(8):2698-2707.
Huang YH, Vakili MR, Molavi O, Morrissey Y, Wu C, Paiva I, Soleimani AH, Sanaee F, Lavasanifar A, Lai R, (2019) Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma. Cancers, 11(2) 248.
PolyGel
Alshamsan A, Abul Kalam M, Reza Vakili M, Binkhathlan Z, Raish M, Ali R, Al-Turki TA, Safaei Nikouei N,Lavasanifar A (2019). Treatment of Endotoxin-Induced Uveitis by Topical Application of Cyclosporine A-LoadedPolyGelTM in Rabbit Eyes. International Journal of Pharmaceutics, 569, 118573.
Makhmalzadeh BS, Molavi O, Vakili MR, Zhang HF, Solimani A, Soleymani Abyaneh H, Loebenberg R, Lai R,Lavasanifar A (2018) Functionalized caprolactone-polyethylene glycol based thermo-responsive hydrogel of silibininfor the treatment of malignant melanoma, Journal of Pharmacy and Pharmaceutical Sciences, 21 (1), 143-159.
Nikouei NS, Ghasemi N, and Lavasanifar A* (2016) “Temperature/pH responsive hydrogels based on poly(ethyleneglycol) and functionalized poly(e-caprolactone) block copolymers for controlled delivery of macromolecules”Pharmaceutical Research, 33(2):358- 66.
Nikouei NS, Vakili MR, Bahniuk MS, Unsworth L. Akbari A. Wu J, Lavasanifar A.(2015) Thermoreversible hydrogelsbased on triblock copolymers of polyethylene glycol) and carboxyl functionalized poly(e-caprolactone) The effect ofcarboxyl group substitution on the transition temperature and biocompatibility in plasma. Acta Biomater. 12:81-92.
Safaei Nikouei N. Lavasanifar A. (2011) Characterization of the thermo- and pH-responsive assembly of triblockcopolymers based on poly(ethylene glycol) and functionalized poly(e-caprolactone). Acta Biomater. 7(10):3708-18.
Contact Us
Questions or Comments?
We know that our clients have unique needs. Send us a message, and we will get back to you soon.
Meros Polymers Inc.
#103, 6033 88 Street NW, Edmonton, Alberta T6E 5T4, Canada
